China Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The china cardiovascular devices market size is expected to grow from USD 3.16 billion in 2025 to USD 3.34 billion in 2026 and is forecast to reach USD 4.41 billion by 2031 at 5.72% CAGR over 2026-2031. This report is Segmented by Device Type (Diagnostic & Monitoring Devices, Therapeutic & Surgical Devices), Application (Coronary Artery Disease, Arrhythmia & Conduction Disorders, Heart Failure & Cardiomyopathy, and More), End-User (Hospitals & Cardiac Centres, Ambulatory Surgical Centres, and More). The Market Forecasts are Provided in Terms of Value (USD).

China Cardiovascular Devices Market Trends and Insights

Rapid expansion of China’s chest-pain centers accrediting advanced interventional device adoption

The national roll-out of chest-pain centers has shortened door-to-balloon intervals to as low as 46.9 minutes, driving stronger uptake of high-performance guidewires, drug-eluting stents, and intravascular imaging systems. Integration of artificial-intelligence triage further lifted primary PCI rates within 90 minutes from 24.47% to 60.41% and pushed connected ECG platforms that cut 30-day mortality from 4.14% to 2.73%. National standards maintained by the Chinese Cardiovascular Association make performance metrics public, prompting county-level hospitals to standardise product choices toward devices demonstrating clinical efficiency. This standardisation increases procurement predictability and compresses time-to-tender for domestic innovators aligned with evidence-based protocols. As the program expands into central and western provinces, device makers that couple competitive pricing with proven clinical outcomes are positioned to capture incremental volumes within the China cardiovascular devices market.

Government “Made in China 2025” initiatives boosting domestic cardiovascular device innovation

The industrial policy goal of 70% domestic supply for mid- to high-end cardiovascular equipment has redirected capital into research pipelines, with leading local firms dedicating 11-14% of sales to R&D, well above the global med-tech average. Resulting product launches span coronary bifurcation stents, pulsed-field ablation systems, and magnetic levitation pumps, all cleared through the National Medical Products Administration’s (NMPA) innovation channel. While foreign brands still dominate complex heart-valve segments, Chinese entrants now match global peers in many delivery-system and polymer-coating technologies, shifting procurement in provincial tenders toward locally registered SKUs. Industry stakeholders expect the localisation push to permeate peripheral vascular and electrophysiology niches by 2027, reinforcing the structural tilt of the China cardiovascular devices market toward home-grown solutions.

Price erosion due to ongoing VBP rounds on high-value consumables

Successive VBP extensions from stents to pacemakers, defibrillators, and valves have saved CNY 260 billion across three years but crimped average selling prices and gross profit margins for premium lines. Multinationals face tougher trade-offs between margin retention and share maintenance, while domestic firms rely on scale economics to protect bottom lines. Although higher volumes cushion revenue, the short-run impact is negative for top-line growth, moderating the overall China cardiovascular devices market CAGR.

Other drivers and restraints analyzed in the detailed report include:

• Rising prevalence of atrial fibrillation in an aging population elevating demand for cardiac rhythm management devices
• Accelerated conditional approval pathway for breakthrough cardiovascular implants by NMPA
• Capacity bottlenecks in qualified cath labs outside top-tier cities

Segment Analysis

Therapeutic and Surgical Devices contributed 67.65% of the China cardiovascular devices market in 2025, buoyed by 2,200 annual coronary interventions at leading centers and VBP-induced volume surges. The cardiac-rhythm-management niche accelerated after NMPA cleared MicroPort Sorin’s new pacing lead in February 2025, underscoring local progress in hermetic sealing and lead-coil metallurgy. Intravascular lithotripsy, renal denervation, and next-gen drug-coated balloons form the emerging wave, with localisation tipping cost-of-goods lower than imports. Over the forecast period, domestic innovators are expected to keep displacing foreign incumbents across mid-complexity implants, reinforcing the primacy of this category within the China cardiovascular devices market.

Diagnostic and Monitoring Devices are projected to expand at a 6.87% CAGR through 2031. AI-enabled ECG analytics integrated into smart wearables bring early detection into homes, while hospital chest-pain networks still buy high-throughput CT and MRI scanners for triage optimisation. Cardiac-biomarker assays backed by local reagent makers support rapid rule-out protocols, serving the 330 million strong patient pool. Cloud-native data platforms align with the NMPA’s revised cybersecurity guidance, helping vendors secure faster approval for software-as-medical-device modules. Given rising chronic-disease management at home, connected diagnostics should keep edging wallet share away from purely interventional SKUs, adding depth to the China cardiovascular devices market size.

Complete Report Scope:

• By Device Type
  • By Product Type
    • Diagnostic & Monitoring Devices
      • ECG Systems
      • Remote Cardiac Monitor
      • Cardiac MRI
      • Cardiac CT
      • Echocardiography / Ultrasound
      • Fractional Flow Reserve (FFR) Systems
    • Therapeutic & Surgical Devices
      • Coronary Stents
        • Drug-Eluting Stents
        • Bare-Metal Stents
        • Bioresorbable Stents
      • Catheters
        • PTCA Balloon Catheters
        • IVUS/OCT Catheters
      • Cardiac Rhythm Management
        • Pacemakers
        • Implantable Cardioverter Defibrillators
        • Cardiac Resynchronization Therapy Devices
      • Heart Valves
        • TAVR/TAVI
        • Mechanical Valves
        • Tissue/Bioprosthetic Valves
      • Ventricular Assist Devices
      • Artificial Hearts
      • Grafts & Patches
      • Other Cardiovascular Surgical Devices
  • By Application
    • Coronary Artery Disease
    • Arrhythmia & Conduction Disorders
    • Heart Failure & Cardiomyopathy
    • Structural & Congenital Heart Defects
    • Peripheral Vascular Disease
  • By End User
    • Hospitals & Cardiac Centres
    • Ambulatory Surgical Centres
    • Cardiology/EP Clinics
    • Home-care & Remote Monitoring Programs

List of Companies Covered in this Report:

• MicroPort
• Lepu Medical Technology (Beijing) Co., Ltd.
• Abbott Laboratories
• Medtronic
• Boston Scientific
• Edward Lifesciences
• Terumo
• Mindray
• Shanghai MicroPort Endovascular MedTech (EMT)
• BIOTRONIK
• Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
• Sino Medical Sciences Technology Inc. (SMST)
• JW Medical Systems Ltd.
• Peijia Medical Limited
• Venus Medtech
• Kewei Medical Instrument Co., Ltd.
• Jiangsu Yuyue Medical Instruments Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support